In 9,718 ambulatory heart failure patients from the pooled EMPEROR trials, low serum chloride (below roughly 99 mmol/L) tracked with higher mortality regardless of sodium. Low sodium (below 140 mmol/L) signalled danger only when chloride was also low; that combination carried 1.3 to 1.7-fold higher rates of heart failure events and death. Empagliflozin's benefit held across every sodium-chloride category (interaction P > 0.1), nudging sodium and chloride up by about 0.1 mmol/L and lowering bicarbonate by 0.2 mmol/L.
Chloride is the neglected electrolyte of heart failure. Clinicians fixate on sodium, yet these data suggest chloride may be the sharper marker of congestion, neurohormonal activation and diuretic exposure, since the high-risk group was more often on loop diuretics. That fits earlier work linking hypochloraemia to diuretic resistance and worse survival. The practical message is modest: a routine metabolic panel already reports chloride, so a low value deserves attention as a flag of advanced disease, not a target to correct in isolation. Association is not causation; chloride may simply mirror disease severity and diuretic dose, and a post hoc trial analysis cannot show that raising chloride improves outcomes. The reassuring finding is that empagliflozin's benefit does not depend on baseline electrolytes, so low sodium or chloride should not deter treatment. The electrolyte shifts themselves are tiny and clinically trivial. Confirmatory and incremental, this sharpens risk stratification without changing management.